India launches first dengue vaccine with strict safety guidelines

India's first dengue vaccine has arrived, but doctors are already warning that it is not for everyone. The vaccine, developed after years of clinical trials, comes with a crucial safety caveat that could determine its success or failure in the country's fight against the mosquito-borne disease.

Who can take the vaccine?

The vaccine is only recommended for people who have had a prior dengue infection. Those who have never been infected with the dengue virus face a higher risk of developing severe dengue if they get the shot. This is because the vaccine can trigger a phenomenon known as antibody-dependent enhancement, where the immune system's response to a first infection is amplified, leading to more serious illness.

Doctors in Kolkata have been explaining the eligibility criteria to patients. The vaccine is not a one-size-fits-all solution. It requires a blood test to confirm past infection before administration. Without this screening, the vaccine could do more harm than good.

Bengaluru doctors call it a significant advance

Despite the restriction, public health experts in Bengaluru have hailed the vaccine as a major milestone. India reports lakhs of dengue cases every year, with thousands of hospitalisations and hundreds of deaths. The vaccine offers a way to protect those who have already been exposed, reducing the risk of severe illness and death.

Doctors at city hospitals say the vaccine could ease the burden on healthcare systems during peak dengue season. They stress that the vaccine is not a replacement for mosquito control measures. It is an additional tool in the public health arsenal.

Clinical trials and development

A private university in Bengaluru conducted clinical trials for the vaccine. The results showed high efficacy in preventing severe dengue among those with prior infection. The trials also confirmed the safety risks for seronegative individuals — those who have never had dengue. The vaccine is now being rolled out in select cities before a wider national launch.

Health officials have not yet confirmed the exact number of doses available or the pricing for the public. The vaccine is expected to be administered in two doses, three months apart.

What happens next?

The vaccine's success will depend on how well doctors and patients follow the screening protocol. If people get the shot without checking their dengue history, the risk of severe disease could rise. Public awareness campaigns are needed to ensure the vaccine reaches the right people. The coming months will show whether India can turn this medical advance into a real public health victory.

Watch for government announcements on phased rollout and pricing in the next few weeks.